Metabolic syndrome and ALA54THR polymorphism of fatty acid–binding protein 2 in obese patients

Abstract The prevalence of metabolic syndrome (MS) has been estimated to be approximately 25% of the population at large. A transition G to A at codon 54 of fatty acid–binding protein 2 ( FABP2 ) results in an amino acid substitution (ala54 to Thr54), and this polymorphism was associated with some c...

Full description

Saved in:
Bibliographic Details
Published in:Metabolism, clinical and experimental clinical and experimental, 2011-05, Vol.60 (5), p.664-668
Main Authors: de Luis, Daniel Antonio, Gonzalez Sagrado, Manuel, Aller, Rocio, Izaola, Olatz, Conde, Rosa
Format: Article
Language:English
Subjects:
Adult
Adults
Analysis
Blood pressure
Blood Pressure - genetics
Cardiorespiratory
Cross-Sectional Studies
Eating
Electric Impedance
Endocrinology & Metabolism
Evaluation
Fatty Acid-Binding Proteins - genetics
Female
Gene Frequency
Humans
Male
Metabolic Syndrome - epidemiology
Metabolic Syndrome - genetics
Middle Aged
Obesity
Obesity - genetics
Patients
Polymorphism, Genetic
Prevalence
Proteins
Risk factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The prevalence of metabolic syndrome (MS) has been estimated to be approximately 25% of the population at large. A transition G to A at codon 54 of fatty acid–binding protein 2 ( FABP2 ) results in an amino acid substitution (ala54 to Thr54), and this polymorphism was associated with some cardiovascular risk factors. The aim of our study was to investigate the relationship between MS and Thr54 polymorphism in the FABP2 gene in obese patients. A population of 750 (body mass index >30) obese patients was analyzed in cross-sectional survey. Bioimpedance, blood pressure, and serial assessment of nutritional intake with 3-day written food records and biochemical analysis were performed. The statistical analysis was performed for the combined Ala54/Thr54 and Thr54/Thr54 as a mutant group and wild-type Ala54/Ala54 as second group. Prevalence of MS with Adult Treatment Panel III definition was 49.7% (373 patients; 24.9% male and 75.1% female), and 50.3% of the patients had no MS (n = 377; 34.2% male and 65.8% female). Prevalence of FABP genotypes was similar in patients with MS (55.5% wild genotype and 44.5% mutant genotype) and without MS (54.6% wild genotype and 45.4% mutant genotype). Prevalence of each criteria of MS was calculated in wild- and mutant-type genotypes, without statistical differences. No differences in anthropometric and biochemical parameters were detected between genotypes in the same group of MS. The finding of our study is the lack of association of the Thr54/Ala54 and Thr54/Thr54 FABP2 genotypes with MS.
ISSN:0026-0495
1532-8600
DOI:10.1016/j.metabol.2010.06.018